Zuber Lawler Earns a Top 5 Spot in Law360’s 2024 Diversity Snapshot Survey, Measuring Diversity Amongst Equity Partners at U.S. Law Firms
July 31, 2024 | Press
Zuber Lawler is proud to announce that it has earned a top-five spot in Law360’s 2024 Diversity Snapshot, which measures diversity in the equity ranks of law firms across the country. Zuber Lawler also ranked in the top-five of all firms with 100 or fewer attorneys participating in the survey nationwide based on the diversity of all partners and associates.
The 2024 law firm survey reveals progress has slowed in diversifying attorney ranks, with only 15.6% of firms meeting diversity benchmarks. In 2023, the law firm survey revealed that 17% of firms had met diversity targets. By comparison, the majority of the occupants of Zuber Lawler’s leadership posts throughout the firm are likewise minorities.
“We are pleased again this year that Zuber Lawler is in the top-five in two categories in the Diversity Snapshot survey with firms of less than 100 attorneys. Holding the number two spot for the diverse number of equity partners and number five of all firms based on the number of partners and associates that participated in the survey.” stated Eileen Letts, the Chicago-based Chief Administrative Partner of the firm. “Our firm takes pride in its diverse workforce. We will continue to be a place where diversity is welcomed, as we all benefit.”
Zuber Lawler’s commitment to diversity is enhanced with the help of Ms. Letts, who is on the Board of Directors of the National Association of Minority and Women-Owned Law Firms (NAMWOLF). Ms. Letts also co-authored the acclaimed book “Left Out and Left Behind,” organized by the Long-Term Careers for Women in Law Initiative and published by the American Bar Association.
Disclaimer: This content may be an attorney advertisement. The information provided on this page does not constitute legal advice. All information, content, and materials available in this post are for general informational purposes only, and might not be up to date. The content on this website is provided “as is,” and no representations are made that the content is free of error. Usage of this website or any resources contained within it does not create an attorney-client relationship between user and any author of relevant content (or any law firm or company of which the author might be a part). Readers of this content should contact their attorney to obtain advice with respect to any particular legal matter. Any and all liability with respect to actions taken or not taken based on the contents of this website are hereby expressly disclaimed.
Recent Updates
An FDA Panel Just Voted to Widen Access to Peptides. Here’s What It Actually Means for the Longevity Space July 30, 2026
Generative AI Legal Issues: 5 Critical Questions Every Business Must Answer Before Deploying AI Solutions May 21, 2026
Medical Rescheduling, Recreational Risk: How Schedule III Could Reshape Adult-Use Cannabis February 18, 2026
Schedule III Cannabis: FDA’s New Frontier January 27, 2026
Data Privacy and AI in Longevity: Legal Risks Around Predictive Biomarkers and Health Data January 23, 2026
2026 Employment Law Developments: Key Takeaways for Employers December 22, 2025